行情

ADMA

ADMA

Adma生物制品
NASDAQ

实时行情|Nasdaq Last Sale

5.32
+0.07
+1.33%
盘后: 5.32 0 0.00% 17:42 09/20 EDT
开盘
5.25
昨收
5.25
最高
5.34
最低
5.10
成交量
318.19万
成交额
--
52周最高
6.72
52周最低
2.080
市值
2.41亿
市盈率(TTM)
-4.2540
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMA 新闻

  • 海湾地区再次转来警报信号 局势已经一触即发?
  • 新浪财经综合.1小时前
  • 通用70亿美元“扑火” 欲减轻电气化对传统岗位冲击
  • 第一财经.1小时前
  • 新加坡这个地标,要拆了
  • 新浪财经综合.1小时前
  • 美股好事多磨藏隐患 两大数据考验美联储降息决心
  • 第一财经.2小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ADMA 简况

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
展开

Webull提供ADMA Biologics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。